cyanocob(III)alamin/Finding
One finding, on its own
A single claim from the graph, with the evidence strength computed from its study, the sentence it was drawn from, and the paper. This address does not change.
cyanocob(III)alamin — no detected effect on alanine aminotransferase
Evidence strength: moderate.FindingNull result“Although serum levels of ALT in the vitamin B12 group decreased significantly, this change did not reach a significant level compared to the placebo group.”
Quoted verbatim from The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.. - Study
- RCT
- Duration
- 3 months
- Dose
- 1000 µg cyanocobalamin, one oral tablet daily for 12 weeks
- Population
- Adults aged 18-80 years with ultrasound-diagnosed non-alcoholic fatty liver disease and raised serum ALT
The effects of vitamin B12 supplementation on metabolic profile of patients with non-alcoholic fatty liver disease: a randomized controlled trial.2022PMID:3598216210.1038/s41598-022-18195-8Industry fundedPermalink
To cite this finding: https://catalystproject.ai/e/01M5MERJA56E71Z6695HZ9JAAN